GE HealthCare Technologies Inc.

What does GE HealthCare do?
GE HealthCare Technologies Inc. develops, manufactures, and sells medical imaging, diagnostics, and healthcare IT solutions. The company operates through four segments: Imaging (MRI, CT, X-ray), Ultrasound, Patient Care Solutions (patient monitoring, healthcare IT), and Pharmaceutical Diagnostics (contrast agents, radiopharmaceuticals). GE HealthCare serves customers in over 160 countries.

Is GE HealthCare publicly traded?
Yes, GE HealthCare Technologies Inc. is publicly traded on the Nasdaq stock exchange under ticker GEHC. The company was spun off from General Electric on January 4, 2023, and has been independently traded since. General Electric does not retain a significant stake.

Who is the CEO of GE HealthCare?
Peter Arduini serves as President and CEO of GE HealthCare. He was appointed to lead GE's healthcare division in 2022 ahead of the January 2023 spinoff and has continued as CEO of the independent company.

What is GE HealthCare's annual revenue?
GE HealthCare reported revenue of $20.1 billion for fiscal year 2025, up from $19.6 billion in 2024. Net income for 2025 was $2.0 billion. The company's growth was driven by strong demand for medical imaging equipment, AI-enabled imaging solutions, and pharmaceutical diagnostics products.

How was GE HealthCare created?
GE HealthCare was created through the spinoff of General Electric's healthcare division on January 4, 2023. The spinoff was part of GE's broader restructuring, which also created GE Vernova (April 2024) and GE Aerospace as independent companies.

What acquisitions has GE HealthCare made recently?
In 2025, GE HealthCare acquired Impact Medical's NMPA-approved AI software for CT imaging analysis, strengthening its position in the Chinese healthcare AI market. The company has also invested in AI-enabled imaging products and digital health platforms.

Where is GE HealthCare headquartered?
GE HealthCare is headquartered in Chicago, Illinois, USA. The company has manufacturing facilities in the United States, United Kingdom, France, China, and India, and serves customers in over 160 countries.

Who owns GE HealthCare?
GE HealthCare is a publicly traded company with a dispersed shareholder base. Institutional investors hold the majority of shares, with no single controlling shareholder. General Electric does not retain a significant stake following the spinoff.

GE HealthCare was formed on January 4, 2023, through the spinoff of General Electric's healthcare division. General Electric had built a significant healthcare business over several decades, developing leading positions in medical imaging including MRI, CT, and ultrasound systems. The healthcare division was a significant part of GE's portfolio with approximately $18 billion in annual revenue at the time of the spinoff.

The spinoff was part of GE's broader restructuring plan, which also included the spinoff of GE Vernova in April 2024. The restructuring created three independent companies: GE HealthCare, GE Vernova, and GE Aerospace, each focused on its respective industry.

Following the spinoff, GE HealthCare focused on operating as an independent company. The company established its own board of directors and management team led by CEO Peter Arduini, who had been appointed to lead GE's healthcare division in 2022 ahead of the spinoff.

In 2023 and 2024, GE HealthCare invested in innovation and digital health. The company launched AI-enabled imaging products and expanded its digital health platform. Revenue grew from $19.6 billion in 2024 to $20.1 billion in 2025, reflecting continued demand for medical imaging and diagnostic equipment.

In 2025, GE HealthCare acquired Impact Medical's AI software for CT imaging analysis, which had received approval from China's National Medical Products Administration (NMPA). This acquisition strengthened the company's position in the Chinese healthcare AI market and expanded its portfolio of AI-enabled imaging solutions.

The company has also focused on precision healthcare, investing in technologies that enable personalized medicine and targeted diagnostics. GE HealthCare's pharmaceutical diagnostics segment has been a key growth area, with contrast agents and radiopharmaceuticals seeing increased demand.

GE HealthCare operates in a highly regulated industry and faces scrutiny related to product safety, regulatory compliance, and healthcare costs.

The company's medical devices are subject to approval by the FDA in the United States, the NMPA in China, the CE mark in Europe, and equivalent regulators in other markets. Product recalls and quality issues can significantly impact brand reputation and financial performance.

In 2025, GE HealthCare's acquisition of Impact Medical's AI software highlighted the growing regulatory complexity of AI-enabled medical devices. AI software for medical imaging requires regulatory approval in each market, and the regulatory landscape for AI in healthcare is still evolving.

The company faces pressure from healthcare providers and payers to control costs, which can affect pricing and margins. Reimbursement policies for medical imaging procedures vary by market and can influence demand for GE HealthCare's products.

GE HealthCare has also faced scrutiny over its manufacturing supply chain, particularly its operations in China and India. The company must navigate geopolitical tensions and trade regulations that could affect its global operations.

As a former GE subsidiary, GE HealthCare inherited some legacy liabilities and legal matters related to GE's healthcare division. The company has been working to resolve these legacy issues while building its independent corporate governance structure.